Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
…
321,110$
0,44%
Echtzeit-Aktienkurs Madrigal Pharmaceuticals
Bid:
Ask:
Nachrichten zur Madrigal Pharmaceuticals Aktie
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Madrigal Pharmaceuticals: Preparing For Resmetiroms Commercialization In 2024
…
Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A Buy Into 2024
…
Madrigal Pharmaceuticals prices of $500 million stock offering
…
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing…
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
: Madrigal Pharmaceuticals shares fall after new CEO named
Shares of Madrigal Pharmaceuticals Inc. MDGL fell more than 7% premarket on Monday after the company appointed Bill Sibold, a…
Madrigal Pharmaceuticals appoints CEO
…
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Paulson takes new stakes in Newmont, Iveric Bio and Madrigal in Q2
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals GAAP EPS of -$4.69
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
CONSHOHOCKEN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Form 8-K MADRIGAL PHARMACEUTICALS For: Aug 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q MADRIGAL PHARMACEUTICALS For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K MADRIGAL PHARMACEUTICALS For: Jul 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment
Madrigal Pharmaceuticals Inc.’s stock MDGL rose 5% Friday after the company said it has started a rolling submission of a…
Madrigal starts rolling submission of US market application for NASH drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal starts rolling submission for NASH drug application with US FDA
...(Reuters) - Madrigal Pharmaceuticals said on Friday it has......…
Madrigal Pharma begins submission of marketing application for NASH drug with US FDA
...June 30 (Reuters) - Madrigal Pharmaceuticals
said on Friday it has......…
Form 8-K MADRIGAL PHARMACEUTICALS For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why did Madrigal Pharma stock drop today? Lilly fatty liver data
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals, Bioventus See Activist Investor Action
Baker Bros. Advisors filed as an activist investor in Madrigal Pharmaceuticals. Juniper Investment lifted its investment in medical-device maker Bioventus....…
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
CONSHOHOCKEN, Pa., June 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing…
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Two key tailwinds appear to be lifting the stock today....…
Madrigal Pharmaceuticals Down 2%; Boosts Stock-Sale Agreement, Reports 1Q
Madrigal Pharmaceuticals Down 2%; Boosts Stock-Sale Agreement, Reports 1Q...…
Form 8-K MADRIGAL PHARMACEUTICALS For: May 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
CONSHOHOCKEN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…
Form 10-Q MADRIGAL PHARMACEUTICALS For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
Two key tailwinds fueled a surge in the biotechs share price this week....…
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector....…
Madrigal Shares Rise 12% After Resmetirom Gets Breakthrough Therapy Designation
Madrigal Shares Rise 12% After Resmetirom Gets Breakthrough Therapy Designation...…
Madrigal rises on FDA breakthrough therapy tag for liver disease drug resmetirom
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K/A MADRIGAL PHARMACEUTICALS For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Senior VP, Chief Pharma Dev. verkauft Aktien von Madrigal Pharmaceuticals im Wert von 1.372.081$
Waltermire, Robert E. - Vorstand - Tag der Transaktion: 2023-03-01...…
Insiderhandel: Senior VP, Chief Pharma Dev. verkauft Aktien von Madrigal Pharmaceuticals im Wert von 1.360.357$
Waltermire, Robert E. - Vorstand - Tag der Transaktion: 2023-02-28...…
Form 8-K MADRIGAL PHARMACEUTICALS For: Feb 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval
Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease....…
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing…
Insiderhandel: Aufsichtsrat verkauft Aktien von Madrigal Pharmaceuticals im Wert von 6.592.686$
Levy, Richard S. - Aufsichtsrat - Tag der Transaktion: 2023-01-17...…
Form 8-K MADRIGAL PHARMACEUTICALS For: Jan 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Madrigal Pharmaceuticals releases additional late-stage data on resmetirom for NASH
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: SVP and General Counsel verkauft Aktien von Madrigal Pharmaceuticals im Wert von 3.677.976$
Lynch, Brian Joseph - Vorstand - Tag der Transaktion: 2023-01-03...…
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
CONSHOHOCKEN, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…